These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8384772)

  • 1. Lysosomal glycosphingolipid storage in chloroquine-induced alpha-galactosidase-deficient human endothelial cells with transformation by simian virus 40: in vitro model of Fabry disease.
    Inagaki M; Katsumoto T; Nanba E; Ohno K; Suehiro S; Takeshita K
    Acta Neuropathol; 1993; 85(3):272-9. PubMed ID: 8384772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysosomal alpha-galactosidase in endothelial cell cultures established from a Fabry hemizygous and normal umbilical veins.
    Hasholt L; Sørensen SA
    Hum Genet; 1986 Jan; 72(1):72-6. PubMed ID: 3002954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme replacement in Fabry endothelial cells and fibroblasts: uptake experiments and electron microscopical studies.
    Hasholt L; Wandall A; Sørensen SA
    Clin Genet; 1988 May; 33(5):360-71. PubMed ID: 2837353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment and characterization of Fabry disease endothelial cells with an extended lifespan.
    Shen JS; Meng XL; Schiffmann R; Brady RO; Kaneski CR
    Mol Genet Metab; 2007; 92(1-2):137-44. PubMed ID: 17644384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α-galactosidase A deficiency promotes von Willebrand factor secretion in models of Fabry disease.
    Kang JJ; Kaissarian NM; Desch KC; Kelly RJ; Shu L; Bodary PF; Shayman JA
    Kidney Int; 2019 Jan; 95(1):149-159. PubMed ID: 30470436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac valvular anomalies in Fabry disease. Clinical, morphologic, and biochemical studies.
    Desnick RJ; Blieden LC; Sharp HL; Hofschire PJ; Moller JH
    Circulation; 1976 Nov; 54(5):818-25. PubMed ID: 824066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chloroquine may induce endothelial injury through lysosomal dysfunction and oxidative stress.
    Gregório P; da Cunha RS; Biagini G; Bosquetti B; Budag J; Ortiz A; Sánchez-Niño MD; Barreto FC; Stinghen AEM
    Toxicol Appl Pharmacol; 2021 Mar; 414():115412. PubMed ID: 33484708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and functional changes in peripheral vasculature of Fabry patients.
    Kalliokoski RJ; Kalliokoski KK; Penttinen M; Kantola I; Leino A; Viikari JS; Simell O; Nuutila P; Raitakari OT
    J Inherit Metab Dis; 2006 Oct; 29(5):660-6. PubMed ID: 16906474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases.
    Ferraz MJ; Marques AR; Appelman MD; Verhoek M; Strijland A; Mirzaian M; Scheij S; Ouairy CM; Lahav D; Wisse P; Overkleeft HS; Boot RG; Aerts JM
    FEBS Lett; 2016 Mar; 590(6):716-25. PubMed ID: 26898341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease.
    Kalliokoski RJ; Kalliokoski KK; Sundell J; Engblom E; Penttinen M; Kantola I; Raitakari OT; Knuuti J; Nuutila P
    J Inherit Metab Dis; 2005; 28(4):563-73. PubMed ID: 15902560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fabry disease: ultrastructural lectin histochemical analyses of lysosomal deposits.
    Kanda A; Nakao S; Tsuyama S; Murata F; Kanzaki T
    Virchows Arch; 2000 Jan; 436(1):36-42. PubMed ID: 10664160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.
    Thurberg BL; Rennke H; Colvin RB; Dikman S; Gordon RE; Collins AB; Desnick RJ; O'Callaghan M
    Kidney Int; 2002 Dec; 62(6):1933-46. PubMed ID: 12427118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pathophysiological aspects of brain structural disturbances in patients with Fabry disease: literature review].
    Nill M; Müller MJ; Beck M; Stoeter P; Fellgiebel A
    Fortschr Neurol Psychiatr; 2006 Dec; 74(12):687-95. PubMed ID: 17167727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fabry disease: an ultrastructural comparative study of skin in hemizygous and heterozygous patients.
    Navarro C; Teijeira S; Dominguez C; Fernandez JM; Rivas E; Fachal C; Barrera S; Rodriguez C; Iranzo P
    Acta Neuropathol; 2006 Feb; 111(2):178-85. PubMed ID: 16463201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Globotriaosylceramide induces lysosomal degradation of endothelial KCa3.1 in fabry disease.
    Choi S; Kim JA; Na HY; Cho SE; Park S; Jung SC; Suh SH
    Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):81-9. PubMed ID: 24158513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular basis for globotriaosylceramide regulation and enzyme uptake in immortalized aortic endothelial cells from Fabry mice.
    Meng XL; Day TS; McNeill N; Ashcraft P; Frischmuth T; Cheng SH; Liu ZP; Shen JS; Schiffmann R
    J Inherit Metab Dis; 2016 May; 39(3):447-455. PubMed ID: 26960552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of renal pathology in Fabry disease.
    Sessa A; Meroni M; Battini G; Righetti M; Nebuloni M; Tosoni A; Vago GL;
    Acta Paediatr Suppl; 2003 Dec; 92(443):6-8; discussion 5. PubMed ID: 14989458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neutral glycosphingolipids of Fabry's disease lymphoblastoid lines established by Epstein-Barr virus transformation].
    Salvayre R; Maret A; Negre A; Douste-Blazy L
    Eur J Biochem; 1985 Feb; 147(1):77-82. PubMed ID: 2982612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α-Galactosidase A-deficient rats accumulate glycosphingolipids and develop cardiorenal phenotypes of Fabry disease.
    Miller JJ; Aoki K; Mascari CA; Beltrame AK; Sokumbi O; North PE; Tiemeyer M; Kriegel AJ; Dahms NM
    FASEB J; 2019 Jan; 33(1):418-429. PubMed ID: 29979634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses.
    Ferraz MJ; Kallemeijn WW; Mirzaian M; Herrera Moro D; Marques A; Wisse P; Boot RG; Willems LI; Overkleeft HS; Aerts JM
    Biochim Biophys Acta; 2014 May; 1841(5):811-25. PubMed ID: 24239767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.